Compare Stocks: REPL, TNGX, TLX, and VKTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
REPL Replimune Group	$15.19 -0.3%	$10.55	$1.50 ▼ $15.71	$1.28B	0.88	8.24 million shs	3.22 million shs
TLX Telix Pharmaceuticals	$12.33 +3.0%	$10.67	$6.28 ▼ $12.60	$4.07B	-0.24	108,278 shs	85,165 shs
TNGX Tango Therapeutics	$25.65 +0.3%	$28.81	$6.25 ▼ $34.39	$4.31B	1.16	2.30 million shs	2.17 million shs
VKTX Viking Therapeutics	$32.94 -3.2%	$34.64	$22.96 ▼ $43.15	$3.97B	0.69	1.91 million shs	3.70 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
REPL Replimune Group	+11.65%	+28.83%	+53.32%	+209.13%	+190.29%
TLX Telix Pharmaceuticals	-0.25%	+14.88%	+9.12%	+10.22%	+10.63%
TNGX Tango Therapeutics	-2.89%	-11.15%	-9.80%	+2.85%	+278.40%
VKTX Viking Therapeutics	+0.65%	+1.52%	-10.76%	+7.28%	-14.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
REPL Replimune Group	$15.19 -0.3%	$10.55	$1.50 ▼ $15.71	$1.28B	0.88	8.24 million shs	3.22 million shs
TLX Telix Pharmaceuticals	$12.33 +3.0%	$10.67	$6.28 ▼ $12.60	$4.07B	-0.24	108,278 shs	85,165 shs
TNGX Tango Therapeutics	$25.65 +0.3%	$28.81	$6.25 ▼ $34.39	$4.31B	1.16	2.30 million shs	2.17 million shs
VKTX Viking Therapeutics	$32.94 -3.2%	$34.64	$22.96 ▼ $43.15	$3.97B	0.69	1.91 million shs	3.70 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
REPL Replimune Group	+11.65%	+28.83%	+53.32%	+209.13%	+190.29%
TLX Telix Pharmaceuticals	-0.25%	+14.88%	+9.12%	+10.22%	+10.63%
TNGX Tango Therapeutics	-2.89%	-11.15%	-9.80%	+2.85%	+278.40%
VKTX Viking Therapeutics	+0.65%	+1.52%	-10.76%	+7.28%	-14.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
REPL Replimune Group	2.60	Moderate Buy	$11.86	-21.94% Downside
TLX Telix Pharmaceuticals	2.63	Moderate Buy	$20.40	65.45% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.31	68.84% Upside
VKTX Viking Therapeutics	2.67	Moderate Buy	$96.63	193.34% Upside

Current Analyst Ratings Breakdown

Latest REPL, TNGX, TLX, and VKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/12/2026	TNGX Tango Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $35.00
8/11/2026	REPL Replimune Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	TNGX Tango Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	VKTX Viking Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$75.00 ➝ $65.00
8/7/2026	REPL Replimune Group	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$12.00
8/7/2026	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$17.00 ➝ $20.00
8/4/2026	REPL Replimune Group	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform
8/4/2026	REPL Replimune Group	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$11.00 ➝ $17.00
7/31/2026	REPL Replimune Group	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$9.00 ➝ $12.00
7/31/2026	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
REPL Replimune Group	N/A	N/A	N/A	N/A	$2.01 per share	N/A
TLX Telix Pharmaceuticals	$803.79M	5.21	$0.04 per share	283.89	$1.23 per share	10.02
TNGX Tango Therapeutics	$62.38M	69.33	N/A	N/A	$2.57 per share	9.98
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$3.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
REPL Replimune Group	-$313.94M	-$3.38	N/A	N/A	N/A	N/A	-128.57%	-82.35%	10/29/2026 (Estimated)
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	112.09	N/A	N/A	N/A	N/A	8/20/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-41.35%	-35.53%	N/A
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)

Latest REPL, TNGX, TLX, and VKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	H1 2026	TLX Telix Pharmaceuticals	$0.0434	N/A	N/A	N/A	$479.63 million	N/A
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A
6/29/2026	Q4 2026	REPL Replimune Group	-$0.6613	-$0.76	-$0.0988	-$0.76	$3.57 million	N/A
5/13/2026	Q1 2026	TNGX Tango Therapeutics	-$0.32	-$0.32	N/A	-$0.32	$0.58 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
REPL Replimune Group	0.63	4.79	4.79
TLX Telix Pharmaceuticals	1.08	1.43	1.27
TNGX Tango Therapeutics	N/A	27.38	27.38
VKTX Viking Therapeutics	N/A	4.72	4.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
REPL Replimune Group	92.53%
TLX Telix Pharmaceuticals	N/A
TNGX Tango Therapeutics	78.99%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
REPL Replimune Group	5.40%
TLX Telix Pharmaceuticals	N/A
TNGX Tango Therapeutics	6.50%
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
REPL Replimune Group	210	84.03 million	79.49 million	Optionable
TLX Telix Pharmaceuticals	1,184	339.78 million	N/A	N/A
TNGX Tango Therapeutics	90	168.61 million	135.25 million	Optionable
VKTX Viking Therapeutics	20	116.65 million	110.47 million	Optionable

REPL, TNGX, TLX, and VKTX Headlines

Recent News About These Companies

JPMorgan Chase & Co. Lowers Viking Therapeutics (NASDAQ:VKTX) Price Target to $65.00

August 13 at 2:01 AM | americanbankingnews.com

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

August 12 at 1:51 PM | finance.yahoo.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Viking Therapeutics (NASDAQ:VKTX) Stock Price

August 11 at 10:59 AM | marketbeat.com

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

August 8, 2026 | fool.com

Royal Bank of Canada Decreases Stock Position in Viking Therapeutics, Inc. $VKTX

August 8, 2026 | marketbeat.com

Viking Therapeutics, Inc. $VKTX Stake Raised by Dimensional Fund Advisors LP

August 8, 2026 | marketbeat.com

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

August 6, 2026 | fool.com

First Trust Advisors LP Acquires Shares of 105,570 Viking Therapeutics, Inc. $VKTX

August 6, 2026 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages

August 6, 2026 | americanbankingnews.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 6, 2026 | marketbeat.com

The Bull Case For Viking Therapeutics (VKTX) Could Change Following New Obesity Dosing Ambitions And Fresh Financing – Learn Why

August 4, 2026 | finance.yahoo.com

Viking Therapeutics (VKTX) Draws Fresh VK2735 Attention, Is It Still Below Fair Value?

August 4, 2026 | finance.yahoo.com

Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says

August 3, 2026 | finance.yahoo.com

Research Analysts Offer Predictions for VKTX Q3 Earnings

August 3, 2026 | americanbankingnews.com

Q3 EPS Estimate for Viking Therapeutics Lifted by Analyst

August 3, 2026 | marketbeat.com

Viking Therapeutics (VKTX) Receives a Buy from Jefferies

August 2, 2026 | theglobeandmail.com

Viking Therapeutics: Why This Clinical-Stage, Licensed-Technology Play Is a Highly Speculative Bet for Equity Investors

August 2, 2026 | theglobeandmail.com

Viking Therapeutics stock moves lower: What's going on?

July 31, 2026 | msn.com

Viking Therapeutics' Q2 Net Loss Widens

July 30, 2026 | finance.yahoo.com

VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs

July 30, 2026 | finance.yahoo.com

VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’

July 30, 2026 | stocktwits.comS

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

REPL, TNGX, TLX, and VKTX Company Descriptions

Replimune Group NASDAQ:REPL

$15.19 -0.05 (-0.33%)

Closing price 04:00 PM Eastern

Extended Trading

$15.16 -0.03 (-0.20%)

As of 06:01 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Telix Pharmaceuticals NASDAQ:TLX

$12.33 +0.36 (+3.01%)

Closing price 04:00 PM Eastern

Extended Trading

$12.32 -0.02 (-0.12%)

As of 05:41 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Tango Therapeutics NASDAQ:TNGX

$25.65 +0.07 (+0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$25.66 +0.01 (+0.02%)

As of 06:01 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$32.94 -1.08 (-3.17%)

Closing price 04:00 PM Eastern

Extended Trading

$32.98 +0.04 (+0.13%)

As of 06:06 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REPL, TNGX, TLX, and VKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REPL, TNGX, TLX, and VKTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REPL, TNGX, TLX, and VKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

REPL, TNGX, TLX, and VKTX Company Descriptions

Replimune Group NASDAQ:REPL

Telix Pharmaceuticals NASDAQ:TLX

Tango Therapeutics NASDAQ:TNGX

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REPL, TNGX, TLX, and VKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REPL, TNGX, TLX, and VKTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REPL, TNGX, TLX, and VKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

REPL, TNGX, TLX, and VKTX Company Descriptions

Replimune Group NASDAQ:REPL

Telix Pharmaceuticals NASDAQ:TLX

Tango Therapeutics NASDAQ:TNGX

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools